^
Association details:
| Biomarker: | TP53 wild-type |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Calquence (acalabrutinib) (BTK inhibitor) + navtemadlin (KRT-232) (MDM2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONI CLYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Published date:
05/11/2023
Excerpt:
This multicenter, global Ph 1b/2 study is enrolling adults with ECOG 0-2, BTKi-naïve, TP53WT R/R CLL/SLL (NCT04502394)….Nvtm combined with acala has an acceptable safety profile with no DLTs in dose escalation and showed encouraging preliminary activity in BTKi-naïve R/R CLL/SLL.
Trial ID:
